spacer
home > > winter 2019 > exploring growth strategies for smaller cros
PUBLICATIONS


Exploring Growth Strategies for Smaller CROs

Over the last several decades, clinical trials have increased in size, cost, complexity, and duration, resulting in sponsors becoming increasingly reliant on the outsourcing services of CROs. The number of countries involved in Phase 3 clinical studies doubled between 2005-15, and the number of investigative sites increased by 63%. Simultaneously, the mean number of patients declined by 18%, adding complexity to the study start-up process and putting greater pressure on CROs to deliver (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Zac Beda is Director and co-founder at Upsilon Global. As Director of Europe and APAC, he is responsible for supporting business development and bid-defence activities for their small/ mid-sized CRO partners, helping them to win more clinical studies, upscale their operations, and cost-effectively launch clinical programmes in new countries and new regions. Their model is built on a global network of clinical, regulatory, and quality affairs consultants, built over three decades of experience within the healthcare industry. Upsilon Global are currently operational in over 50 countries across six continents.
spacer
Zac Beda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed with BioNTech to use Novartis manufacturing plant in Stein, Switzerland, to support production of mRNA COVID-19 vaccine Production to commence in the second quarter for estimated delivery commencing in the third quarter 2021
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement